See how we're growing and where we're going

Product and event news: Check back often for the latest information on our portfolio, convention engagements, and booth numbers.

  • GREENSTONE LLC INTRODUCES CELECOXIB CAPSULES—Its Latest Generic Pharmaceutical Product

    PEAPACK, N.J., December 2014 — Greenstone LLC, a U.S.-based subsidiary of Pfizer Inc. (NYSE: PFE), is pleased to announce the introduction of CELECOXIB to its ever-expanding generic pharmaceutical product line. The product is offered in capsule form in dosage strengths of 50 mg x 60 capsules per bottle; 100 mg x 100 capsules per bottle; 100 mg x 500 capsules per bottle; 200 mg x 100 capsules per bottle; 200 mg x 500 capsules per bottle; and 400 mg x 60 capsules per bottle. Read more »

  • GREENSTONE LLC INTRODUCES CABERGOLINE TABLETS—Its Latest Generic Pharmaceutical Product

    PEAPACK, NJ, September 2014 — Greenstone LLC, a U.S.-based subsidiary of Pfizer Inc (NYSE: PFE), is pleased to announce the introduction of cabergoline tablets to its ever-expanding generic pharmaceutical product line. The product is offered in tablet form in dosage strengths of 0.5 mg x eight tablets per bottle. Read more »

  • GREENSTONE LLC INTRODUCES SIROLIMUS TABLETS—Its Latest Generic Pharmaceutical Product

    PEAPACK, N.J., November 2014 — Greenstone LLC, a U.S.-based generic pharmaceutical subsidiary of Pfizer Inc. (NYSE: PFE), announced, on October 27, 2014, the introduction of sirolimus tablets to its ever-expanding generic pharmaceutical product line. The product is offered as 1 mg and 2 mg tablets in bottles of 100 tablets each. Read more »

  • GREENSTONE LLC INTRODUCES DOXAZOSIN MESYLATE TABLETS—Its Latest Generic Pharmaceutical Product

    PEAPACK, NJ, July 2014 — Greenstone LLC, a U.S.-based subsidiary of Pfizer Inc (NYSE: PFE), is pleased to announce the introduction of Doxazosin Mesylate tablets to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strengths of 1 mg x 100; 2 mg x 100; 4 mg x 100 and 8 mg x 100. Read more »

  • GREENSTONE LLC INTRODUCES NADOLOL TABLETS—Its Latest Generic Pharmaceutical Product

    PEAPACK, N.J., May 2014 — Greenstone LLC, a U.S.-based subsidiary of Pfizer Inc. (NYSE: PFE), is pleased to announce the introduction of Nadolol tablets to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strengths of 20 mg x 100; 40 mg x 100 and 80 mg x 100. Read more »

  • GREENSTONE LLC INTRODUCES RIFABUTIN CAPSULES—Its Latest Generic Pharmaceutical Product

    PEAPACK, N.J., April 2014 — Greenstone LLC, a U.S.-based generic pharmaceutical subsidiary of Pfizer Inc. (NYSE: PFE), is pleased to announce the introduction of Rifabutin Capsules to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strength of 150mg x 100. Read more »

  • GREENSTONE LLC INTRODUCES PIROXICAM CAPSULES—Its Latest Generic Pharmaceutical Product

    PEAPACK, N.J., March 2014 — Greenstone LLC, a U.S.-based generic pharmaceutical subsidiary of Pfizer Inc. (NYSE: PFE), is pleased to announce the introduction of Piroxicam Capsules to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strengths of 10mg x 100 and 20mg x 100. Read more »

  • GREENSTONE LLC INTRODUCES TOLTERODINE TARTRATE TABLETS—Its Latest Generic Pharmaceutical Product

    PEAPACK, N.J., January, 2014 — Greenstone LLC, a U.S.-based generic pharmaceutical subsidiary of Pfizer Inc. (NYSE: PFE), is pleased to announce the introduction of Tolterodine Tartrate Tablets to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strengths of 1mg x 60; 1mg x500; 2mg x 60 and 2mg x500. Read more »

  • Product Recall

    Pfizer initiates voluntary recall of two lots of Pfizer's EFFEXOR XR® 150 mg extended-release capsules and one lot of Greenstone's VENLAFAXINE HCL 150 mg extended-release capsules. Read more »

  • GREENSTONE LLC INTRODUCES SIROLIMUS—Its Latest Generic Pharmaceutical Product

    PEAPACK, N.J., January 2014 — Greenstone LLC, a U.S.-based generic pharmaceutical subsidiary of Pfizer Inc. (NYSE: PFE), is pleased to announce the introduction of Sirolimus to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strengths of 0.5mg x 100. Read more »

  • GREENSTONE LLC INTRODUCES VORICONAZOLE FOR ORAL SUSPENSION—Its Latest Generic Pharmaceutical Product

    PEAPACK, N.J., December 2013 — Greenstone LLC, a U.S.-based generic pharmaceutical subsidiary of Pfizer Inc. (NYSE: PFE), is pleased to announce the introduction of Voriconazole for Oral Suspension to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strengths of 40mg/mL bottle. Read more »

  • GREENSTONE LLC INTRODUCES ATORVASTATIN CALCIUM TABLETS—Its Latest Generic Pharmaceutical Product

    PEAPACK, N.J., January 2013—Greenstone LLC, a U.S.-based generic pharmaceutical subsidiary of Pfizer Inc. (NYSE: PFE), is pleased to announce the introduction of Atorvastatin Calcium Tablets to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strength of 10mg x 90; 10mg x 1,000; 20mg x 90; 20mg x 1,000; 40mg x 90; 40mg x 500; 80mg x 90; 80mg x 500. Read more »

News Archive»

About GREENSTONE. GREENSTONE LLC, established in 1993, is a wholly owned subsidiary of Pfizer Inc, one of the largest pharmaceutical companies in the world. GREENSTONE, which focuses on customer service, markets a broad line of quality authorized generics—along with an expanding line of ANDA (Abbreviated New Drug Application) generics. GREENSTONE authorized generics, well known for having the same physical characteristics as the innovators' brands, are supported by state-of-the-art distribution and operations services. GREENSTONE is working with numerous brand pharmaceutical companies to assist in their "post-exclusivity" planning, with a focus on authorized generics. The company offers a robust product pipeline that highlights quality generic equivalents to some of the best-selling branded pharmaceuticals. GREENSTONE LLC will continue to offer numerous future product opportunities for pharmacies and its trade partners.

Download Catalog

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.